{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:06:47Z","timestamp":1792750007422,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.survophthal.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T10:44:21Z","timestamp":1748083461000},"page":"1067-1089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"70","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1120672117750058","article-title":"A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion","volume":"28","author":"Bandello","year":"2018","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.05.008_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070459","article-title":"Angiopoietin-2 is critical for cytokine-induced vascular leakage","volume":"8","author":"Benest","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.survophthal.2025.05.008_bib4","unstructured":"Bradbury N., Field R., Nevill C., et al. Meta Insight: v6.3.0 [Internet]. Res Syn Meth; 2019 [cited 2025 Mar 14]. Available from: https:\/\/crsu.shinyapps.io\/MetaInsight\/."},{"issue":"10432","key":"10.1016\/j.survophthal.2025.05.008_bib5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.05.008_bib7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmol [Internet]"},{"issue":"7","key":"10.1016\/j.survophthal.2025.05.008_bib8","first-page":"1370","article-title":"INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial","volume":"39","author":"Casselholm de Salles","year":"2019","journal-title":"Retin Philos Pa"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib9","article-title":"Characteristics of major and macular branch retinal vein occlusion","volume":"12","author":"Choi","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.survophthal.2025.05.008_bib10","doi-asserted-by":"crossref","first-page":"P288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal Vein Occlusions Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib11","first-page":"27","article-title":"Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases","volume":"1","author":"Green","year":"1981","journal-title":"Retin Philos Pa"},{"issue":"3","key":"10.1016\/j.survophthal.2025.05.008_bib12","first-page":"271","article-title":"Group. Argon laser photocoagulation for macular edema in branch vein occlusion","volume":"98","year":"1984","journal-title":"Branch Vein Occlusion Study Group Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.05.008_bib13","first-page":"1434","article-title":"Group study. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion","volume":"102","year":"1995","journal-title":"Cent Vein Occlusion Study Group N Report Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib14","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib15","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/aos.13381","article-title":"Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)","volume":"96","author":"Hattenbach","year":"2018","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"7","key":"10.1016\/j.survophthal.2025.05.008_bib16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib17","first-page":"1","article-title":"THE ANGIOPOIETIN\/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review","volume":"41","author":"Heier","year":"2021","journal-title":"Retin Philos Pa"},{"key":"10.1016\/j.survophthal.2025.05.008_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","article-title":"Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study","volume":"169","author":"Hoerauf","year":"2016","journal-title":"Am J Ophthalmol [Internet]"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001010","article-title":"Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review","volume":"7","author":"Hunter","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib20","first-page":"40","article-title":"Retinal Vein Occlusion Review","volume":"7","author":"Ip","year":"2018","journal-title":"Asia-Pac J Ophthalmol Philos Pa"},{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1600-0420.2005.00592.x","article-title":"Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases","volume":"83","author":"Jonas","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"10.1016\/j.survophthal.2025.05.008_bib22","first-page":"1305","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye Lond Engl"},{"issue":"12","key":"10.1016\/j.survophthal.2025.05.008_bib23","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.survophthal.2025.05.008_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255182","article-title":"Changes in peripapillary and subfoveal choroidal thickness in patients with central retinal vein occlusion","volume":"16","author":"Kang","year":"2021","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.survophthal.2025.05.008_bib25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2025.05.008_bib26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"D\u2019Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"10432","key":"10.1016\/j.survophthal.2025.05.008_bib28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib29","first-page":"901","article-title":"Efficacy of panretinal laser in ischemic central retinal vein occlusion: A systematic review","volume":"17","author":"Li","year":"2019","journal-title":"Exp Ther Med"},{"issue":"9","key":"10.1016\/j.survophthal.2025.05.008_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231198388","article-title":"Progress in central retinal artery occlusion: a narrative review","volume":"51","author":"Liu","year":"2023","journal-title":"J Int Med Res"},{"issue":"8","key":"10.1016\/j.survophthal.2025.05.008_bib31","first-page":"1656","article-title":"Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study","volume":"36","author":"Lotery","year":"2022","journal-title":"Eye Lond Engl"},{"issue":"3","key":"10.1016\/j.survophthal.2025.05.008_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/APO.0000000000000286","article-title":"Chorioretinal Anastomosis for Central Retinal Vein Occlusion: A Review of Its Development, Technique, Complications, and Role in Management","volume":"9","author":"McAllister","year":"2020","journal-title":"Asia-Pac J Ophthalmol Philos Pa"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10792-024-03158-x","article-title":"Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial","volume":"44","author":"Meng","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"19","key":"10.1016\/j.survophthal.2025.05.008_bib35","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.survophthal.2025.05.008_bib36","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.05.008_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.oftal.2020.06.013","article-title":"Central retinal artery occlusion as a post-transfusion complication of red blood cells","volume":"96","author":"Ortiz Zapata","year":"2021","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.survophthal.2025.05.008_bib38","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ [Internet]"},{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1159\/000527626","article-title":"Anti-Vascular Endothelial Growth Factor Treatment Compared with Steroid Treatment for Retinal Vein Occlusion: A Meta-Analysis","volume":"245","author":"Patil","year":"2022","journal-title":"Ophthalmol [Internet]"},{"issue":"2","key":"10.1016\/j.survophthal.2025.05.008_bib40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/APO.0000000000000602","article-title":"Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data","volume":"12","author":"Radke","year":"2023","journal-title":"Asia-Pac J Ophthalmol [Internet"},{"key":"10.1016\/j.survophthal.2025.05.008_bib41","unstructured":"Regeneron. EYLEA HD\u00ae (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion | Regeneron Pharmaceuticals Inc. [Internet]. EYLEA HD\u00ae (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion. 2024 [cited 2025 Mar 14]. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/eylea-hdr-aflibercept-injection-8-mg-phase-3-trial-meets-primary\/."},{"issue":"9","key":"10.1016\/j.survophthal.2025.05.008_bib42","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","article-title":"Retinal vein thrombosis: pathogenesis and management","volume":"8","author":"Rehak","year":"2010","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.survophthal.2025.05.008_bib43","article-title":"Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications","volume":"27","author":"Rho","year":"2023","journal-title":"Am Heart J Cardiol Res Pr"},{"issue":"2","key":"10.1016\/j.survophthal.2025.05.008_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/tjo.tjo_9_17","article-title":"Management of macular edema due to central retinal vein occlusion \u2013 The role of aflibercept","volume":"7","author":"Rhoades","year":"2017","journal-title":"Taiwan J Ophthalmol [Internet]"},{"issue":"9","key":"10.1016\/j.survophthal.2025.05.008_bib45","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.survophthal.2025.05.008_bib46","first-page":"123","article-title":"Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)","volume":"242","author":"Schmidt-Erfurth","year":"2019","journal-title":"Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd"},{"issue":"12","key":"10.1016\/j.survophthal.2025.05.008_bib47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaophthalmol.2019.3947","article-title":"Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial","volume":"137","author":"Scott","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib48","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1186\/s12967-024-05441-y","article-title":"Insights to Ang\/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases","volume":"22","author":"Sha","year":"2024","journal-title":"J Transl Med [Internet]"},{"key":"10.1016\/j.survophthal.2025.05.008_bib49","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.survophthal.2025.05.008_bib50","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmol [Internet]"},{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib51","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","article-title":"Individualized Stabilization Criteria\u2013Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER","volume":"123","author":"Tadayoni","year":"2016","journal-title":"Ophthalmol [Internet]"},{"issue":"6","key":"10.1016\/j.survophthal.2025.05.008_bib52","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","article-title":"Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial","volume":"4","author":"Vader","year":"2020","journal-title":"Ophthalmol Retin [Internet]"},{"issue":"1","key":"10.1016\/j.survophthal.2025.05.008_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.oret.2019.08.001","article-title":"Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study","volume":"4","author":"Wei","year":"2020","journal-title":"Ophthalmol Retin [Internet]"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:57:45Z","timestamp":1758542265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725000967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0039625725000967"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.05.008","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}